Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...

Boehringer Ingelheim partners with the WHO Foundation to financially support WHO’s Fourteenth General Programme of Work (2025 to 2028). Credit: PeopleImages.com – Yuri A/Shutterstock. Boehringer ...

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's Breakthrough Therapy for the review of their experimental weight-loss drug for the ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

Forbes lists are exclusively determined by our editorial team. We do not accept payment for consideration or selection.

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

The Angelika Amon research building is named after a Viennese pioneer in cell biology who was closely connected with Boehringer Ingelheim. Image credit: Boehringer Ingelheim. Boehringer Ingelheim has ...

The clinical pipeline is constantly being further developed, and Boehringer Ingelheim expects new approvals also in oncology in the coming years. An important investment in the future is the new ...

Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis ...

The clinical pipeline is constantly being further developed, and Boehringer Ingelheim expects new approvals also in oncology in the coming years. An important investment in the future is the new ...